Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported continued progress across its clinical and corporate initiatives for the third quarter of 2025, underscoring growing momentum in its mission to bring the first approved treatment for patients with Netherton Syndrome.
“The third quarter of 2025 has been a period of significant momentum and strategic advancement for Quoin Pharmaceuticals,” said Dr. Michael Myers, Chief Executive Officer. “We are very pleased by the continued positive clinical data emerging from our ongoing studies in Netherton Syndrome as well as the encouraging data in Peeling Skin Syndrome. The appointment of Sally Lawlor as our new Chief Financial Officer further strengthens our leadership team as we prepare for the next phase of growth and commercialization.”
Dr. Myers added that the company’s NETHERTON NOW awareness campaign “has totally shattered all expectations,” surpassing 1.5 million views since its February launch and continuing to raise awareness for patients, families, and caregivers affected by Netherton Syndrome.
Corporate Highlights
- Private Placement Financing: Quoin completed a private placement financing of up to $105.3 million in October 2025, including $16.6 million in initial funding and up to $88.7 million upon potential exercise of warrants. The financing strengthens the company’s balance sheet and provides capital to fund operations, advance the clinical development of QRX003 for Netherton Syndrome, and support its Peeling Skin Syndrome and topical rapamycin programs.
- Regulatory Milestone: Received FDA Orphan Drug Designation for QRX003 for the treatment of Netherton Syndrome.
- Clinical Expansion: Expanded the pediatric Netherton clinical program based on positive long-term safety and efficacy data.
- Leadership Update: Appointed Sally Lawlor as Chief Financial Officer to support commercialization and financial operations.
- Advocacy Impact: The NETHERTON NOW campaign achieved over 1.5 million video views and 14 million impressions within six months of launch, amplifying global awareness for Netherton Syndrome.
- Pipeline Advancement: Released positive Peeling Skin Syndrome data and announced plans for study expansion.
- Next Milestone: Recruitment for both pivotal QRX003 clinical trials in Netherton Syndrome is expected to begin in Q4 2025.
Financial Highlights
As of September 30, 2025, Quoin held approximately $5.4 million in cash, cash equivalents, and marketable securities. Combined with recent funding and warrant exercises totaling $19.9 million, the company expects its cash position to support operations into 2027.
The post Quoin Pharmaceuticals Reports Strong Q3 Progress and Expands Clinical Programs appeared first on PRISM MarketView.
